Eldred Rock Partners LLC boosted its position in Novartis AG by 12.2% during the third quarter, adding 9,871 shares to total 90,753 shares. At quarter end, the holding was valued at approximately $11.64 million, representing 2.9% of the firm’s portfolio and ranking as its 18th largest stake. This move underscores continued confidence by a value‐oriented investor in Novartis’s long‐term growth prospects.

In its latest quarterly report, Novartis delivered earnings per share of $2.25, narrowly missing consensus estimates by $0.01. Revenue rose 8.5% year-over-year to $14.36 billion, comfortably ahead of the $13.70 billion analyst consensus. Return on equity stood at 41.21%, while net margins reached 26.49%, reflecting strong operational leverage in core pharmaceutical segments despite modest EPS headwinds.

Novartis reported a debt‐to‐equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.68, indicating conservative leverage and liquidity profiles. With a market capitalization near $291.2 billion, the group trades at a P/E ratio of 18.8 and a P/E/G ratio of 1.96. A beta of 0.52 points to lower volatility relative to the broader market, supporting its defensive pharmaceutical pedigree.

Analyst coverage remains broad, with one firm holding a Strong Buy view, five recommending Buy, six at Hold and three at Sell. Recent reissues include overweight and hold designations by Morgan Stanley, Jefferies and CFRA. Based on aggregated research, the consensus rating sits at Hold, with an average target price of $119.75, suggesting limited upside from current levels.